Showing 61-80 of 498 for: Cochrane Systematic Reviews > Neurologic 
- Beta‐blocker therapy for tremor in Parkinson's disease
Cochrane Systematic Reviews, 20-Jan-2003
The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as
- Betahistine for Ménière's disease or syndrome
Cochrane Systematic Reviews, 22-Jan-2001
This is an update of a Cochrane Review first published in The Cochrane Library in Issue 1, 2001 and previously updated in 2008.
- Biopsy versus resection for high‐grade glioma
Cochrane Systematic Reviews, 6-Jun-2019
This is an update of the original review published in the Cochrane Database of Systematic Reviews Issue 1, 2000 and updated in 2003, 2007 and 2010.
- Biopsychosocial rehabilitation for upper limb repetitive strain injuries in working age adults
Cochrane Systematic Reviews, 4-Nov-2008
Upper limb repetitive strain injury is a common problem in western countries, causing human suffering and huge economical losses. Patients with prolonged pain associated with repetitive tasks in the work place can face both psychological and physical diff
- Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)
Cochrane Systematic Reviews, 20-Jan-2010
Cerebral palsy (CP) is "a group of permanent disorders of the development of movement and posture causing activity limitation(s) that are attributed to non-progressive disturbance that occurred in the developing fetal or infant brain" (Rosenbaum 2007, p.9
- Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy
Cochrane Systematic Reviews, 8-Oct-2019
Cerebral palsy (CP) is the most common cause of physical disabilities in children in high-income countries. Spasticity is the most common motor disturbance in CP. Botulinum toxin type A (BoNT-A) is considered the first-line treatment for focal spasticity
- Bradykinin beta-2 receptor antagonists for acute traumatic brain injury
Cochrane Systematic Reviews, 20-May-2010
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Cerebral oedema, the accumulation of fluid within the brain, is believed to be an important contributor to the secondary brain damage that occurs following injury. The rele
- Bright light therapy for sleep problems in adults aged 60+
Cochrane Systematic Reviews, 22-Apr-2002
The prevalence of sleep problems in adulthood increases with age. While not all sleep changes are pathological in later life, severe disturbances may lead to depression, cognitive impairments, deterioration of quality of life, significant stresses for car
- Bromocriptine for levodopa‐induced motor complications in Parkinson's disease
Cochrane Systematic Reviews, 27-Jul-1998
Motor Complications are an important issue in the management of patients with Parkinson's disease and dopamine agonists have been introduced to ameliorate this problem.
- Bromocriptine versus levodopa in early Parkinson's disease
Cochrane Systematic Reviews, 17-Oct-2007
Drugs that mimic dopamine as bromocriptine were introduced as monotherapy or in combination with LD in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). However, hitherto, the ro
- Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease
Cochrane Systematic Reviews, 17-Oct-2007
Drugs that mimic dopamine, such as bromocriptine (BR), were introduced as monotherapy or in combination with levodopa (LD) in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). Ho
- Cabergoline for levodopa‐induced complications in Parkinson's disease
Cochrane Systematic Reviews, 22-Jan-2001
Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can
- Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease
Cochrane Systematic Reviews, 22-Jan-2001
Long term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can
- Calcium antagonists as an add‐on therapy for drug‐resistant epilepsy
Cochrane Systematic Reviews, 28-Mar-2013
This is an updated version of the original Cochrane review published in The Cochrane Library 2001, Issue 4.
- Calcium channel blockers for acute traumatic brain injury
Cochrane Systematic Reviews, 20-Oct-2003
Acute traumatic brain injury is a major cause of death and disability. Calcium channel blockers (calcium antagonists) have been used in an attempt to prevent cerebral vasospasm after injury, maintain blood flow to the brain, and so prevent further damage.
- Calcium channel blockers for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 26-Mar-2018
Schizophrenia and related disorders affect a sizable proportion of any population. Antipsychotic medications are the primary treatment for these disorders. Antipsychotic medications are associated with a variety of adverse effects including tardive dyskin
- Cannabinoids for epilepsy
Cochrane Systematic Reviews, 5-Mar-2014
Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy.
- Cannabinoids for the treatment of dementia
Cochrane Systematic Reviews, 15-Apr-2009
Following the discovery of an endogenous cannabinoid system and the identification of specific cannabinoid receptors in the central nervous system, much work has been done to investigate the main effects of these compounds. There is increasing evidence th
- Cannabinoids for Tourette's Syndrome
Cochrane Systematic Reviews, 7-Oct-2009
Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side eff
- Carbamazepine for chronic neuropathic pain and fibromyalgia in adults
Cochrane Systematic Reviews, 10-Apr-2014
This is an update of a Cochrane review entitled 'Carbamazepine for acute and chronic pain in adults' published in Issue 1, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review
